Link Genomics' three main pipelines based on our newly developed technology of genes and proteins analysis are;

(1) Target for Anti-cancer Drugs
(2) Developing an Early Diagnostic Marker of Cancer
(3) Supplying a Marker for Pathologic Diagnosis of Cancer


Link Genomics invests human/material resources to develop the early stage of drug production, and supplies our developed materials to companies which involve in the later stages of drug production such as clinical trials, manufacturing, marketing.

Collaboration with numerous academic and clinical institutes and alliance with pharmaceutical companies are one of our essential strategy.

We are also offering various services which include the in vitro evaluation and analysis of target molecules or drug candidate compounds, as well as the drug re-profiling to pharmaceutical companies, academic and clinical institutes, etc.

Three Main Projects to Conquer Cancer

1. Target for Anti-cancer Drugs

We are trying to discover and evaluate the "Molecular Target Drug", which can selectively attack the specific molecules in cancer with little side-effect.
　

3. Supplying a Marker for Pathologic Diagnosis of Cancer

A database on patients' own genome and proteome-based information is valuable in choosing the way of medical treatment to deal with various pathological diagnosis of cancer, Link Genomics is developing diagnostic technology on the basis of the correlation between patients' conditions and markers.